About: http://data.cimple.eu/news-article/11f9220d4bc6a3be1172a940c5d12b9a25f94db9a610d789e80eb769

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/11f9220d4bc6a3be1172a940c5d12b9a25f94db9a610d789e80eb769 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	The arthritis drug tocilizumab has shown early promise in preventing extreme inflammation in gravely ill COVID-19 patients, according to a French clinical study. The treatment, which suppresses the body's natural immune response, was found to reduce "significantly" the number of deaths or life support interventions compared with a control group of patients. The study, carried out by the Paris university hospital trust (AP-HP), looked at 129 people hospitalised with moderate or severe viral pneumonia, which occurs in 5-10 percent of COVID-19 patients. Half received two injections of tocilizumab as well as standard treatment with antibiotics, while the control group received only standard treatment. While the results are yet to be published, those involved in the research said it showed clear "clinical benefit" of tocilizumab treatment. AP-HP said it had decided to publicise the study before publishing official results "for public health reasons". They stressed however that further research was needed on the effectiveness of the drug and the potential for side effects. Tocilizumab, sold under the brand names Actemra and RoAcemtra, is commonly used to treat rheumatoid arthritis. It is a lab-synthesised antibody that inhibits against a specific protein receptor involved in the body's natural immune response. Researchers believe the drug might be able to stave off a state of heightened immune response known as cytokine storms -- where the body's reaction to a foreign body such as a disease or chemical creates acute inflammation. Cytokine storms can be deadly and occur in severely ill COVID-19 patients. Tocilizumab currently costs around 800 euros ($870) per injection. Several existing drugs, including anti-viral medicines, are currently being trialled worldwide for COVID-19 treatment. abb/pg/bsp
schema:headline	Arthritis drug shows 'significant' promise in severe COVID-19 cases: study
schema:mentions	Teaching hospital Mechanical ventilation Inflammation Arthritis French language Antibiotic Protein Public health Antibody Immune system Paris Severe acute respiratory syndrome coronavirus 2 Foreign body Immune receptor Viral pneumonia Tocilizumab Assistance Publique – Hôpitaux de Paris Cytokine Rheumatoid arthritis
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2020-04-28 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	negative sentiment
http://data.cimple...readability_score	80 (xsd:integer)
http://data.cimple...tology#hasEmotion	happiness

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 3 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software